AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06199323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Description: The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula).
Study NCT01323777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study NCT00981968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxentan sodium/Placebo
Description: 100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
Study NCT00981968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxentan sodium/Placebo
Description: 100 mg and 200 mg, tablet, single oral dose
Study NCT00159783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Asenapine, 40 weeks
Study NCT00159783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 40 weeks
Study NCT03104387 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electric train
Description: Exposure to air with low level of ultrafine particles (Electric train)
Study NCT03104387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel train
Description: Exposure to air with high level of ultrafine particles (Diesel train)
Study NCT02709655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day
Description: 10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Study NCT02709655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Description: 20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Study NCT02709655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20mg/day
Description: 20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
Study NCT02709655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablet, orally
Study NCT01006824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: Capsule endoscopy
Study NCT01006824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dedicated small bowel contrast radiography
Description: Dedicated small bowel contrast radiography
Study NCT02220816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive training
Description: 30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
Study NCT02220816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Competitive Training
Description: 30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
Study NCT03107806 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OptiScanner®
Description: 1. Glucose monitoring by OptiScanner® for 48 h~2. Glucose lowering intervention (insulin) guided by OptiScanner®
Study NCT04716855 — intervention group
Intervention type: OTHER
Intervention: Quality of life and daily living activities assessment tests
Study NCT03949855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.
Study NCT03949855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Belimumab
Description: The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.
Study NCT03949855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6.
Study NCT03949855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6.
Study NCT00468910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Given orally
Study NCT00468910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00468910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT00468910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative study
Study NCT04569331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimulation of efferent loop
Description: Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery.
Study NCT04569331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation pelvic floor
Description: 3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
Study NCT01734486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.9 UI/kg/week. Subcutaneous injection for 3 years
Study NCT01734486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 1.8 UI/kg/week. Subcutaneous injection for 3 years
Study NCT02622100 — intervention group
Intervention type: DEVICE
Intervention: Bioresorbable Vascular Scaffold
Study NCT02607254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
Study NCT02607254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
Study NCT04825145 — intervention group
Intervention type: OTHER
Intervention: Pregnancy
Description: Pregnancies complicated by preeclampsia
Study NCT00441441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: fluticasone propionate 100mcg HFA
Study NCT00441441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol
Description: fluticasone propionate/salmeterol 100/50mcg HFA
Study NCT02929849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg SC
Description: Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
Study NCT02929849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg SC
Description: Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
Study NCT02929849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule given with breakfast (mixed meal tolerance test)
Study NCT03791645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sky Intervention
Description: SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (\~3 hours/day), followed by 4 weekly follow-ups (\~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
Study NCT01313806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator
Description: Treatment group vs. Placebo group
Study NCT01313806 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Resonator Device
Study NCT01062620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXL1717
Description: Phase I study with increasing dosage and treatment duration
Study NCT02932189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
Study NCT01354353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally
Study NCT01354353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Administered orally
Study NCT06011330 — intervention group
Intervention type: DRUG
Intervention: Fruquintinib combined with anti-PD-1 antibodies
Description: Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
Study NCT01022567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendicectomy
Description: Standard appendicectomy
Study NCT01022567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
Study NCT04348591 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Restructuring
Description: All participants will learn how to change their thinking in order to be less upset when confronted with stressors
Study NCT04348591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: All participants will learn how to change their thinking in order to be less upset when confronted with stressors
Study NCT00320606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression Withdrawal
Description: Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
Study NCT03984825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
Study NCT03984825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Portia
Description: Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
Study NCT02478151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrganOx Metra
Description: Normothermic machine perfusion (NMP) Metra device
Study NCT04348591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neurostimulation
Description: all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
Study NCT04348591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurostimulation
Description: all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
Study NCT03754062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Administration of Placebo by pill.
Study NCT03754062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Administration of L-dopa by pill.
Study NCT03754062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Administration of Haloperidol by pill.
Study NCT05004142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c+Fulvestrant
Description: FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
Study NCT05004142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c+Letrozole+Goserelin
Description: FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
Study NCT03102359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
Study NCT03102359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Helmet
Description: Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
Study NCT01836744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Survival rate dental implant (OsseoSpeed™)
Study NCT04466501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACR LAB
Description: The ACR \| LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
Study NCT04109235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training Physical Activity (PA) Advice
Description: This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
Study NCT04109235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Population-Based Physical Activity (PA) Advice
Description: This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4\&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
Study NCT03159377 — intervention group
Intervention type: DEVICE
Intervention: Ultra low dose chest CT
Description: Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
Study NCT00948662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-760
Description: SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
Study NCT00948662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of SAM-760
Description: SAM-760 matching placebo capsule, single dose, 1 day,
Study NCT00948662 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketoconazole
Description: Ketoconazole oral tablets, 200 mg bid, 14 days
Study NCT00242385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor
Description: Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
Study NCT00242385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose of 60 mg/kg alpha1-proteinase inhibitor
Description: Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
Study NCT04552379 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon beta-1a
Description: Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at \~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use.
Study NCT03858062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy (with or without glucose sensor)
Description: Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
Study NCT03858062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial pancreas (Inreda Diabetic)
Description: Bi-hormonal reactive closed loop system without mealtime announcement
Study NCT02871115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy Intervention
Description: Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
Study NCT02871115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
Study NCT02862821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HR-EEG